Included in the formulation
АТХ:A.10.B.F.02 Miglitol
A.10.B.F Inhibitors of alpha glucosidase
Pharmacodynamics:Competitively inhibits alpha-glucosidase on the brush border of the small intestine epithelium, which take part in the final stage of digestion of carbohydrates. Miglitol slows the cleavage of di-, oligo- and polysaccharides to glucose and inhibits its absorption, and also has a positive effect on lipid metabolism. The most effective at a normal level of glucose on an empty stomach and in combination with other hypoglycemic drugs.
Pharmacokinetics:Virtually completely absorbed when taking low doses. Binding to plasma proteins - less than 4%, half-life - 2-3 hours. It is not biotransformed, excreted by the kidneys in unchanged form, in small quantities excreted with bile.
Indications:Diabetes mellitus type II.
IV.E10-E14.E11 Non-insulin-dependent diabetes mellitus
Contraindications:Syndrome malabsorption in chronic diseases of the intestine.
Remkheld's syndrome.
Hernias of large sizes.
Nonspecific ulcerative colitis.
Intestinal stricture.
Creatinine clearance below 25 ml / min.
Pregnancy and the period of breastfeeding.
Age to 18 years.
Individual intolerance.
Pregnancy and lactation:FDA Action Category - B. The drug is contraindicated in pregnancy and during breastfeeding.
Dosing and Administration:The drug should be taken immediately before meals or during meals, with a small amount of water. The initial dose is 50 mg once before bedtime. With good tolerability, the dose can be increased to 300-600 mg per day in 3 divided doses.
Side effects:Metabolism: Hypoglycemia in combination with other antidiabetic agents.
Digestive system: discomfort, bloating, diarrhea.
Others: increased activity of transaminases, allergic reactions.
Overdose:When an overdose is observed feeling of overflow in the stomach, swelling and abdominal pain, loose stools. It is necessary to exclude the use of food and beverages containing carbohydrates for 5 hours, symptomatic therapy is prescribed.
Interaction:Enhances the hypoglycemic effect of other antidiabetic drugs and laxatives with simultaneous use.
Antacids, cholestyramine, intestinal adsorbents, digestive enzymes reduce the effectiveness of the drug with simultaneous administration.
Miglitol with a joint application reduces the bioavailability of metformin, the absorption of propranolol and ranitidine.
Special instructions:When developing hypoglycemia, glucose should be prescribed.